Flamel
Technologies S.A. (FLML) is a pharmaceutical company that specializes
in developing and commercializing innovative drug delivery systems.
The company's products and services are used in a range of therapeutic
areas, including pain management, diabetes, and rare diseases. Flamel
Technologies is headquartered in Lyon, France.
Flamel
Technologies had a market capitalization of approximately $92 million.
The company's total revenue for the fiscal year 2020 was $94.7
million, representing an increase from $66.9 million in the previous
year. Net income for the same period was $6.3 million, an improvement
from a net loss of $21.2 million in the previous year.
Flamel
Technologies has a strong focus on innovation, and has been recognized
for its advanced drug delivery technologies and solutions. The
company's products are marketed through a network of partners and
distributors in the United States, Europe, and other markets around
the world.
The company faces competition from other
pharmaceutical companies that operate in the same therapeutic areas,
as well as from emerging technologies and new market entrants.
However, Flamel Technologies' strong track record of innovation,
experienced management team, and strategic partnerships should
position it well for continued success in the future.
Flamel
Technologies' stock is listed on the NASDAQ stock exchange under the
ticker symbol FLML. Investors should carefully consider their
investment objectives, risk tolerance, and other factors before
investing in Flamel Technologies or any other pharmaceutic
|
